E. Philpot

1.8k total citations
51 papers, 1.1k citations indexed

About

E. Philpot is a scholar working on Immunology and Allergy, Physiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, E. Philpot has authored 51 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Immunology and Allergy, 37 papers in Physiology and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in E. Philpot's work include Allergic Rhinitis and Sensitization (39 papers), Asthma and respiratory diseases (35 papers) and Respiratory and Cough-Related Research (20 papers). E. Philpot is often cited by papers focused on Allergic Rhinitis and Sensitization (39 papers), Asthma and respiratory diseases (35 papers) and Respiratory and Cough-Related Research (20 papers). E. Philpot collaborates with scholars based in United States, United Kingdom and Canada. E. Philpot's co-authors include Kathleen Rickard, Melissa Faris, Barbara A. Prillaman, Cindy K. Cook, Anna Ellsworth, Wei Wu, Frank C. Hampel, Eli O. Meltzer, Harold B. Kaiser and Paul H. Ratner and has published in prestigious journals such as Blood, PEDIATRICS and CHEST Journal.

In The Last Decade

E. Philpot

50 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Philpot United States	20	973	936	336	281	134	51	1.1k
Robert Berkowitz United States	14	329 0.3×	498 0.5×	287 0.9×	95 0.3×	58 0.4×	24	684
Zev M. Munk United States	11	184 0.2×	338 0.4×	241 0.7×	40 0.1×	20 0.1×	14	410
D. Häfner Germany	8	148 0.2×	251 0.3×	139 0.4×	11 0.0×	53 0.4×	12	393
J. Prat Spain	12	44 0.0×	162 0.2×	143 0.4×	4 0.0×	6 0.0×	33	375
Yoshihisa Ishiura Japan	13	22 0.0×	290 0.3×	248 0.7×	15 0.1×	4 0.0×	37	413
I Wahedna United Kingdom	8	44 0.0×	312 0.3×	230 0.7×	9 0.0×	5 0.0×	13	432
L.A. Danielson United States	8	66 0.1×	97 0.1×	37 0.1×	5 0.0×	33 0.2×	10	516
Anne‐Marie Kirsten Germany	18	25 0.0×	658 0.7×	852 2.5×	4 0.0×	5 0.0×	43	970
Sivan Weiss Israel	6	104 0.1×	442 0.5×	315 0.9×	1 0.0×	9 0.1×	9	556
Chantale Diba Australia	11	26 0.0×	361 0.4×	387 1.2×	4 0.0×	3 0.0×	11	499

Countries citing papers authored by E. Philpot

Since Specialization

Citations

This map shows the geographic impact of E. Philpot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Philpot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Philpot more than expected).

Fields of papers citing papers by E. Philpot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Philpot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Philpot. The network helps show where E. Philpot may publish in the future.

Co-authorship network of co-authors of E. Philpot

This figure shows the co-authorship network connecting the top 25 collaborators of E. Philpot. A scholar is included among the top collaborators of E. Philpot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Philpot. E. Philpot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Philpot, E., et al.. (2022). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Alternative Pathway Masp-3 Inhibitor OMS906 in a Phase 1 Study of Healthy Subjects. Blood. 140(Supplement 1). 5801–5802. 2 indexed citations

Hoffmann‐Vold, Anna‐Maria, Toby M. Maher, E. Philpot, Ali Ashrafzadeh, & Oliver Distler. (2021). Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. ERJ Open Research. 7(1). 235–2020. 16 indexed citations

Hoffmann‐Vold, Anna‐Maria, Toby M. Maher, E. Philpot, Ali Ashrafzadeh, & Oliver Distler. (2019). OP0064 EVIDENCE-BASED CONSENSUS RECOMMENDATIONS FOR THE IDENTIFICATION AND MANAGEMENT OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS. Annals of the Rheumatic Diseases. 78. 104–104. 5 indexed citations

Meltzer, Eli O., et al.. (2010). Comparison of patient preference for sensory attributes of fluticasone furoate or fluticasone propionate in adults with seasonal allergic rhinitis: a randomized, placebo-controlled, double-blind study. Annals of Allergy Asthma & Immunology. 104(4). 331–338. 15 indexed citations

Philpot, E., et al.. (2010). Pilot Study of Fluticasone Furoate Nasal Spray Administered Once Daily in Subjects with Irritant (Non-Allergic) Rhinitis Triggered by Air Pollution. Journal of Allergy and Clinical Immunology. 125(2). AB82–AB82. 1 indexed citations

Patel, Deepen, et al.. (2008). Lack of effect on adult and adolescent hypothalamic-pituitary-adrenal axis function with use of fluticasone furoate nasal spray. Annals of Allergy Asthma & Immunology. 100(5). 490–496. 19 indexed citations

Meltzer, Eli O., et al.. (2008). Efficacy and safety of once‐daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 wk. Pediatric Allergy and Immunology. 20(3). 279–286. 25 indexed citations

Meltzer, Eli O., et al.. (2008). Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: A randomized, multicenter, double-blind, single-dose, crossover study. Clinical Therapeutics. 30(2). 271–279. 21 indexed citations

Nathan, Robert A., William E. Berger, William H. Yang, et al.. (2008). Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Annals of Allergy Asthma & Immunology. 100(5). 497–505. 46 indexed citations

10.

Kaiser, Harold B., et al.. (2007). Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 119(6). 1430–1437. 114 indexed citations

11.

Hampel, Frank C., et al.. (2007). Once-daily Fluticasone Furoate∗ Nasal Spray (FF) Provides 24-hour Symptom Relief In Subjects With Seasonal Allergic Rhinitis (SAR) Caused By Mountain Cedar Pollen ∗USAN approved name. Journal of Allergy and Clinical Immunology. 119(1). S304–S305. 5 indexed citations

12.

Given, John, et al.. (2007). Once-Daily Fluticasone Furoate∗ Nasal Spray (FFNS) 110mcg Improves Quality of Life (QoL) in Subjects with Seasonal Allergic Rhinitis (SAR) during the ragweed season ∗USAN approved name. Journal of Allergy and Clinical Immunology. 119(1). S304–S304. 2 indexed citations

13.

Andrews, Charles P., et al.. (2006). Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms. Annals of Allergy Asthma & Immunology. 96(6). 851–857. 40 indexed citations

14.

Nathan, Robert A., Steven W. Yancey, Barbara A. Prillaman, et al.. (2005). Fluticasone Propionate Nasal Spray Is Superior to Montelukast for Allergic Rhinitis While Neither Affects Overall Asthma Control. CHEST Journal. 128(4). 1910–1920. 32 indexed citations

15.

Sheth, Ketan, Cindy K. Cook, E. Philpot, et al.. (2004). Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function.. PubMed. 25(2). 115–20. 16 indexed citations

16.

Bernstein, David I., Frank C. Hampel, Charlotte A. Baidoo, et al.. (2004). Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clinical & Experimental Allergy. 34(6). 952–957. 68 indexed citations

17.

Philpot, E., et al.. (2004). The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis.. PubMed. 24(5). 331–7. 56 indexed citations

18.

Dykewicz, Mark S., Harold B. Kaiser, Robert A. Nathan, et al.. (2003). Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn). Annals of Allergy Asthma & Immunology. 91(1). 44–48. 34 indexed citations

19.

Ratner, Paul H., William C. Howland, E. Philpot, et al.. (2003). Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Annals of Allergy Asthma & Immunology. 90(5). 536–542. 61 indexed citations

20.

Philpot, E.. (2000). Safety of Second Generation Antihistamines. Allergy and Asthma Proceedings. 21(1). 15–20. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact